EISA Presents: Ready, Steady, Grow! Evening Seminar
Giving the opportunity to meet investors, funders, entrepreneurs and business advisers to find out about the various funding options all in one place at one time!
At the offices of BDO, 55 Baker Street, London W1U 7EU
Please book via our Eventbrite page here.
PLEASE NOTE: Places are free but in the event of non-attendance or cancellations, less than 24 hrs in advance, an administration fee of £30 per attendee will be charged.
More speakers to be confirmed.
Chris Barrett is a proactive Angel Investor, focusing on early-stage opportunities – typically with intellectual property or smart solutions in the B2B space. His investments range from niche fashion brands and media to Med Tech and specialist chemicals. Career experience ranges from start-ups to FTSE 100 including media, finance and energy in roles of creator, developer and project and programme manager.
Now working with both pre- and post-investment ventures, he seeks to establish synergies and value chains within his broad portfolio of early stage and listed investments. As a supporter of EIS, he networks actively across the funding and advisory ecosystem.
David Brookes is a tax partner at BDO LLP specialising in SEIS/EIS and VCTs and heads up the firm’s Venture Capital Taxes team. David acts for venture capital funds, companies seeking to qualify for venture capital investment and high net worth individual investors. He provides tax advice to companies from start-ups raising Series 1 capital to flotations on AIM and the main market.
David writes the Venture Capital Taxes text book published by Bloomsbury professional and sits on the EIS Association Tax and Technical Committee.
Dr Tina Flatau, Managing Director MedAnnex Ltd. Tina has worked in pharmaceutical and biotechnology R&D for over 25 years. A Principal in PwC’s Pharmaceutical Industry Group, since 2002 she has worked in a management and advisory capacity for pharmas and start-ups in the biopharmaceutical sector. From 2009 to 2014 Tina was VP of R&D Operations at RNA modulation company Prosensa Therapeutics – NASDAQ:[RNA] 2013 – a rare disease developer spun out from Leiden University with funds from patient groups, non-dilutive grants, individual and corporate investors, as well as big pharma. Tina regards mixed models of early development funding partners as the new ‘normal’, relationships with strategic partners in academia, industry and patient organisations are all core to success. Since 2016 Tina has been working with Edinburgh-based start-up MedAnnex Ltd, working in annexin-A1 modulation. Tina is a Trustee of the rare disease research charity Action Duchenne.
Emma Jones, Enterprise Nation Following a degree in Law and Japanese, Emma joined international accounting firm Arthur Andersen, where she worked in London, Leeds and Manchester offices and set up the firm’s Inward Investment practice that attracted overseas companies to locate in the UK.
In 2000, bitten by the dot.com bug, Emma left the firm to start her first business, Techlocate. After 15 months, the company was successfully sold to Tenon plc. The experience of starting, growing and selling a business from a home base gave Emma the idea for Enterprise Nation which was launched in 2006 as the home business website.
The company has since expanded to become a small business membership community of over 75,000 people who benefit from events and support: online and in person.Enterprise Nation also presents a campaigning voice to government and the media on behalf of its members.
Richard Moore joined Calculus Capital in 2013. Prior to this he was a Director at Citigroup, which he joined in 2005, and previously worked at JPMorgan and Strata Technology Partners; resulting in over 14 years of corporate finance experience and a large base of industry contacts. Since joining Calculus, Richard specialises in advising companies in the technology industry and has worked with a number of our portfolio companies including Quai and ActiveOps.
Richard began his career at KPMG where he qualified as a Chartered Accountant, and remains a member of the ACAEW. He has a BA (Hons) in Politics and Economics from Durham University.
Previously an entrepreneur himself, Scott Simpkin joined Europe’s leading equity crowdfunding platform Seedrs as a Campaigns Associate in April 2017. Scott’s role at Seedrs is to work with businesses from the very beginning of the fundraising journey, helping these businesses undergo a successful campaign. In the last year Scott has helped over 20 businesses such as Mercato Metropolitano and Spare Fruit successfully complete their equity crowdfunding campaign on Seedrs. Holding a 95% success rate, Scott’s campaigns on Seedrs over the last year have raised over £10 million on the platform. Outside of Seedrs, Scott is a keen runner and can occasionally be found tweeting about Aldershot Town Football Club or attending rock concerts.
Mark Twigg has been a Director at Cicero for 14 years. He is currently overseeing the firm’s expanding international research business. A prolific writer and researcher, Mark has undertaken largescale longitudinal studies on behalf of Aegon, BlackRock, HSBC and Scottish Widows.
Mark is also active in UK and EU government relations across a number of Cicero’s blue chip corporate clients dealing with international financial regulation, tax policy and retail financial services. He currently sits on the American Chamber of Commerce EU financial services committee and tax task force. Previously, Mark previously worked for the UK Labour Government between 1997-1999 for both the Rt. Hon Nick Brown MP and the Rt. Hon John Reid MP. He also worked as an adviser to the UK Treasury-sponsored Bischoff Review.
He worked as head of government relations at Direct Line Group, lobbying across the RBS insurance brands, during which time he also served on a number of ABI and CEA (Insurance Europe) Committees. Mark has extensive international experience in the Americas, Europe, the Middle East and Asia.